ReviewPaediatric drugs2017
Fibromyalgia: Treating Pain in the Juvenile Patient.
Review in Paediatric drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Management of Juvenile Fibromyalgia: A Level I Evidence-Based Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Pharmacologic Management of Pain in Children: Balancing Evidence, Safety, and Clinical Challenges.Children (Basel, Switzerland) · 2026Review
- Acute Pain in Children with Chronic Musculoskeletal Pain: A Prospective Controlled Study of Intensive Interdisciplinary Treatment.Children (Basel, Switzerland) · 2025Article
- The Feasibility and Acceptability of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain: A Single-Arm Pilot Trial.Children (Basel, Switzerland) · 2022Article
- VOSviewer-Based Bibliometric Network Analysis for Evaluating Research on Juvenile Primary Fibromyalgia Syndrome (JPFS).Children (Basel, Switzerland) · 2022Review
- Juvenile primary fibromyalgia syndrome: A Review- Treatment and Prognosis.Pediatric rheumatology online journal · 2021Review
- Longitudinal Impact of Parental Catastrophizing on Child Functional Disability in Pediatric Amplified Pain.Journal of pediatric psychology · 2021Article
- Suicidal risk and resilience in juvenile fibromyalgia syndrome: a cross-sectional cohort study.Pediatric rheumatology online journal · 2021Article
- Beyond Amitriptyline: A Pediatric and Adolescent Oriented Narrative Review of the Analgesic Properties of Psychotropic Medications for the Treatment of Complex Pain and Headache Disorders.Children (Basel, Switzerland) · 2020Review
- Prevalence of Juvenile Fibromyalgia Syndrome Among Children and Adolescents and its Relationship With Academic Success, Depression and Quality of Life, Çorum Province, Turkey.Archives of rheumatology · 2020Article
- Chronic idiopathic musculoskeletal pain in youth: a qualitative study.Pediatric rheumatology online journal · 2019Observational
- Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.Pediatric rheumatology online journal · 2019Observational
- The juvenile fibromyalgia syndrome (JFMS): a poorly defined disorder.Acta bio-medica : Atenei Parmensis · 2019Review
- Chronic Widespread Pain and Fibromyalgia Syndrome: Life-Course Risk Markers in Young People.Pain research & management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Presently, evidence for the efficacy of medications for the treatment of juvenile fibromyalgia syndrome (JFMS) is limited. While there are medications approved by the US Food and Drug Administration (duloxetine, milnacipran and pregabalin) for adults with fibromyalgia syndrome, there are none for the treatment of JFMS. A variety of medications have been prescribed for the treatment of JFMS, including (but not limited to) non-opioid analgesics, opioids, anticonvulsants, antidepressants, and muscle relaxants. Psychological therapies, most prominently cognitive behavioral therapy, are the most evidenced-based treatment modalities for JFMS. A multidisciplinary approach, combining pharmacological, behavioral and exercise-based modalities is currently the standard of care for JFMS. In the future, more stringent randomized, controlled trials with longer follow-up periods are needed in order to determine the long-term efficacy and safety of medications in the treatment of JFMS. Additionally, improved recognition of JFMS will allow for better patient recruitment to permit for adequately powered study designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.